- Home
- JFR vs SDGR Comparison
JFR vs SDGR Comparison
Compare JFR & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFR
- SDGR
- Stock Information
- Founded
- JFR 2004
- SDGR 1990
- Country
- JFR United States
- SDGR United States
- Employees
- JFR N/A
- SDGR N/A
- Industry
- JFR Trusts Except Educational Religious and Charitable
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- JFR Finance
- SDGR Health Care
- Exchange
- JFR Nasdaq
- SDGR Nasdaq
- Market Cap
- JFR 1.1B
- SDGR 1.5B
- IPO Year
- JFR N/A
- SDGR 2020
- Fundamental
- Price
- JFR $8.57
- SDGR $21.12
- Analyst Decision
- JFR
- SDGR Buy
- Analyst Count
- JFR 0
- SDGR 4
- Target Price
- JFR N/A
- SDGR $33.75
- AVG Volume (30 Days)
- JFR 621.7K
- SDGR 1.2M
- Earning Date
- JFR 01-01-0001
- SDGR 07-30-2025
- Dividend Yield
- JFR 11.31%
- SDGR N/A
- EPS Growth
- JFR N/A
- SDGR N/A
- EPS
- JFR N/A
- SDGR N/A
- Revenue
- JFR N/A
- SDGR $230,492,000.00
- Revenue This Year
- JFR N/A
- SDGR $24.44
- Revenue Next Year
- JFR N/A
- SDGR $22.17
- P/E Ratio
- JFR N/A
- SDGR N/A
- Revenue Growth
- JFR N/A
- SDGR 22.29
- 52 Week Low
- JFR $7.61
- SDGR $16.60
- 52 Week High
- JFR $8.82
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- JFR 74.32
- SDGR 46.38
- Support Level
- JFR $8.47
- SDGR $20.28
- Resistance Level
- JFR $8.59
- SDGR $22.15
- Average True Range (ATR)
- JFR 0.04
- SDGR 0.79
- MACD
- JFR 0.01
- SDGR 0.15
- Stochastic Oscillator
- JFR 89.39
- SDGR 59.34
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.